Baseline Predictors of Clinical Remission in Children With Uncontrolled, Moderate-to-Severe Asthma Treated With Dupilumab: A Post Hoc Analysis of The VOYAGE Study

Andrew Moraco, Sanofi, Cambridge, MA; Leonard Bacharier, Vanderbilt University Medical Center, Nashville, SD, United States; Nikolaos G. Papadopoulos, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS GREECE, Athens, Attiki, Greece; Daniel J. Jackson, University of Wisconsin School of Medicine and Public Health, Oregon, WI, United States; Antoine Deschildre, CHU Lille, Lille, Nord-Pas-de-Calais, France; Theresa W. Guilbert, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Olivier Ledanois, Sanofi, Paris, Ile-de-France, France; Rebecca Gall, Regeneron Pharmaceuticals, Sleepy Hollow, NY, United States